fabrazyme 35mg injection
sanofi-aventis (malaysia) sdn. bhd. - recombinant human alfa galactosidase (r-hagal) -
galafold
amicus therapeutics europe limited - migalastat hydrochloride - fabry disease - migalastat - galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of fabry disease (α-galactosidase a deficiency) and who have an amenable mutation.
galafold capsule
amicus therapeutics canada inc. - migalastat (migalastat hydrochloride) - capsule - 123mg - migalastat (migalastat hydrochloride) 123mg - other miscellaneous therapeutic agents
amikacin 100 mg/2ml fresenius injection
fresenius kabi manufacturing sa (pty) ltd - injection - see ingredients - each 2 ml vial contains amikacin sulphate equivalent to 100 mg amikacin
amikacin 500 mg/2ml fresenius injection
fresenius kabi manufacturing sa (pty) ltd - injection - see ingredients - each 2 ml vial contains amikacin sulphate equivalent to 500 mg amikacin
amikacin 1 g/4 ml fresenius injection
fresenius kabi manufacturing sa (pty) ltd - injection - see ingredients - each 4 ml solution contains amikacin sulphate equivalent to 1 g amikacin
replagal infusion (parenteral)
takeda (pty) ltd - infusion (parenteral) - see ingredients - each 1,0 ml solution contains agalsidase alfa 1,0 mg
plaquenil 200 milligram film coated tablet
b & s healthcare - hydroxychloroquine sulfate - film coated tablet - 200 milligram
plaquenil 200 milligram film coated tablet
imed healthcare ltd. - hydroxychloroquine sulfate - film coated tablet - 200 milligram
plaquenil 200mg film-coated tablets
sanofi-aventis ireland limited t/a sanofi - hydroxychloroquine sulfate - film-coated tablet - 200 milligram(s) - aminoquinolines; hydroxychloroquine